Adaptor molecules PAG, NTAL and LAT in physiological lymphocyte precursors and in childhood leukaemia
Authors:
K. Švojgr 1,2; T. Burjanivová 1,2; M. Vášková 1,2; T. Kalina 1,2; T. Brdička 3; T. Kačerová 3; J. Starý 2; J. Trka 1,2; J. Zuna 1,2
Authors‘ workplace:
CLIP – Childhood Leukaemia Investigation Prague
1; Klinika dětské hematologie a onkologie UK 2. LF a FN, v Motole, Praha
2; Oddělení molekulární imunologie, Ústav molekulární genetiky AV ČR, Praha
3
Published in:
Transfuze Hematol. dnes,15, 2009, No. 2, p. 107-113.
Category:
Comprehensive Reports, Original Papers, Case Reports
Overview
Transmembrane adaptor proteins do not posses an enzymatic or kinase function, but they mediate signal transmission from cell surface to the nucleus. In animal model, changes in PAG adaptor molecule expression induce a leukaemia-like phenotype. In this study, adaptor molecules PAG, LAT, NTAL were analysed in physiological lymphocyte precursors and in 75 diagnostic samples of childhood acute lymphoblastic leukaemia (ALL). The expression status was assessed at mRNA level (using real-time quantitative reverse-transcriptase polymerase chain reaction) and at protein level (using flow cytometry). During a physiological maturation of lymphocyte precursors an expression status of some adaptors shows significant dynamics among distinct maturation stages. Among different ALL subgroups different adaptor molecules expression dynamics can be seen, particularly in TEL/AML1 patients displaying a unique profile of expression. NTAL level at the diagnosis of T-ALL has a prognostic impact predicting good or poor response to initial corticosteroid treatment. This observation was confirmed in in vitro assay – after incubation with corticoids a percentage of surviving cells is higher in wild-type T-ALL cell line compared to the same cells with transfected NTAL gene.
Key words:
acute lymphoblastic leukaemia, adaptor proteins, tumour immunity, prognosis
Sources
1. Horejsi V, Zhang W, Schraven B. Transmembrane adaptor proteins: organizers of immunoreceptor signalling. Nat Rev Immunol 2004; 4: 603–616.
2. Hancock JF. Lipid rafts: contentious only from simplistic standpoints. Nat Rev Mol Cell Biol 2006; 7: 456–462.
3. Brdicka T, Pavlistova D, Leo A, et al. Phosphoprotein associated with glycosphingolipid-enriched microdomains (PAG), a novel ubiquitously expressed transmembrane adaptor protein, binds the protein tyrosine kinase csk and is involved in regulation of T cell activation. J Exp Med 2000; 191: 1591–1604.
4. Horejsi V. Transmembrane adaptor proteins in membrane microdomains: important regulators of immunoreceptor signaling. Immunol Lett 2004; 92: 43–49.
5. Posevitz-Fejfar A, Smida M, Kliche S, Hartig R, Schraven B, Lindquist JA. A displaced PAG enhances proximal signaling and SDF-1-induced T cell migration. Eur J Immunol 2008; 38: 250–259.
6. Smida M, Posevitz-Fejfar A, Horejsi V, Schraven B, Lindquist JA. A novel negative regulatory function of the phosphoprotein associated with glycosphingolipid-enriched microdomains: blocking Ras activation. Blood 2007; 110: 596–615.
7. Svec A, Velenska Z, Horejsi V. Expression pattern of adaptor protein PAG: correlation between secondary lymphatic follicle and histogenetically related malignant lymphomas. Immunol Lett 2005; 100: 94–97.
8. Baumgartner M, Angelisova P, Setterblad N, et al. Constitutive exclusion of Csk from Hck-positive membrane microdomains permits Src kinase-dependent proliferation of Theileria-transformed B lymphocytes. Blood 2003; 101: 1874–1881.
9. Zhang W, Sommers CL, Burshtyn DN, et al. Essential role of LAT in T cell development. Immunity 1999; 10: 323–332.
10. Su YW, Jumaa H. LAT links the pre-BCR to calcium signaling. Immunity 2003; 19: 295–305.
11. Su YW, Herzog S, Lotz M, Feldhahn N, Muschen M, Jumaa H. The molecular requirements for LAT-mediated differentiation and the role of LAT in limiting pre-B cell expansion. Eur J Immunol 2004; 34: 3614–3622.
12. Brdicka T, Imrich M, Angelisova P, et al. Non-T cell activation linker (NTAL): a transmembrane adaptor protein involved in immunoreceptor signaling. J Exp Med 2002; 196: 1617–1626.
13. Wang Y, Horvath O, Hamm-Baarke A, et al. Single and combined deletions of the NTAL/LAB and LAT adaptors minimally affect B-cell development and function. Mol Cell Biol 2005; 25: 4455–4465.
14. Stork B, Engelke M, Frey J, et al. Grb2 and the non-T cell activation linker NTAL constitute a Ca(2+)-regulating signal circuit in B lymphocytes. Immunity 2004; 21: 681–691.
15. Zhu M, Koonpaew S, Liu Y, et al. Negative regulation of T cell activation and autoimmunity by the transmembrane adaptor protein LAB. Immunity 2006; 25: 757–768.
16. Tedoldi S, Paterson JC, Hansmann ML, et al. Transmembrane adaptor molecules: a new category of lymphoid-cell markers. Blood 2006; 107: 213–221.
17. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995; 9: 1783–1786.
18. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156–159.
19. Boublikova L, Kalinova M, Ryan J, et al. Wilms’ tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia 2006; 20: 254–263.
20. Kalina T, Vaskova M, Mejstrikova E, et al. Myeloid antigens in childhood lymphoblastic leukemia: clinical data point to regulation of CD66c distinct from other myeloid antigens. BMC Cancer 2005; 5: 38.
21. Vaskova M, Fronkova E, Starkova J, Kalina T, Mejstrikova E, Hrusak O. CD44 and CD27 delineate B-precursor stages with different recombination status and with an uneven distribution in nonmalignant and malignant hematopoiesis. Tissue Antigens 2008; 71: 57–66.
22. Zuna J, Krejci O, Madzo J, et al. TEL/AML1 and immunoreceptor gene rearrangements-which comes first? Leuk Res 2005; 29: 633–639.
23. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression dynamics during germinal center transit in B cells. Ann N Y Acad Sci 2003; 987: 166–172.
24. Finco TS, Kadlecek T, Zhang W, Samelson LE, Weiss A. LAT is required for TCR-mediated activation of PLCgamma1 and the Ras pathway. Immunity 1998; 9: 617–626.
Labels
Haematology Internal medicine Clinical oncologyArticle was published in
Transfusion and Haematology Today
2009 Issue 2
Most read in this issue
- Microchimerism – on the edge of incipient AML relapse?
- Clonal evolution in chronic lymphocytic leukemia
- Interfant 99 – treatment reflecting unique biology of the infant acute lymphoblastic leukemia. The results in the Czech Republic
- Novel aproaches in therapy of low-risk patients with myelodysplastic syndrome